Work

Sglt2 Inhibitors Beyond Diabetes a Retrospective Audit of Prescribing Patterns in Patients With Heart Failure With Preserved Ejection Fraction

Year: 2026

Type: conference-paper

Abstract: Heart failure with preserved ejection fraction (HFpEF) constitutes a substantial and increasing proportion of heart failure cases worldwide, with historically limited evidence-based therapeutic options. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, initially developed for the management of type 2 diabetes mellitus, have demonstrated significant cardiovascular benefits, including reductions in heart failure hospitalizations and improvement in functional outcomes, irrespective of glycemic status. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.20127369

Authors: Mehak Nazeem, Haleema Iqbal ,, Nayab Nisar, Saifullah,

Institution: Samarkand State Medical Institute

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7160870919

FWCI:

Cites:

Cited by:

Related to: